Dornase alfa

Dornase alfa, sold under the brand name Pulmozyme, is used for the treatment of cystic fibrosis.^[3] It is a recombinant human deoxyribonuclease I (rhDNase), an enzyme which selectively cleaves DNA.^[3] Dornase alfa hydrolyzes the DNA present in sputum/mucus and reduces viscosity in the lungs, promoting improved clearance of secretions.^[3] It is produced in Chinese hamster ovary cells.^[3]

Dornase alfa

Clinical data
Trade names	Pulmozyme
AHFS/Drugs.com	Monograph
MedlinePlus	a694002
License data	US DailyMed: Dornase alfa
Pregnancy category	AU: B1[1]
Routes of administration	Inhalation
ATC code	R05CB13 (WHO)
Legal status
Legal status	AU: S4 (Prescription only)[1] CA: ℞-only / Schedule D[2] US: ℞-only[3] In general: ℞ (Prescription only)
Identifiers
CAS Number	143831-71-4 N
DrugBank	DB00003 Y
ChemSpider	none
UNII	953A26OA1Y
KEGG	D03896
CompTox Dashboard (EPA)	DTXSID801010888
ECHA InfoCard	100.029.685
Chemical and physical data
Formula	C1321H1999N339O396S9
Molar mass	29254.04 g·mol−1
NY (what is this?)  (verify)

Medical uses

Dornase alfa is indicated for the management of people with cystic fibrosis to improve pulmonary function.^[3]

Society and culture

Legal status

Dornase alfa is an orphan drug.^[4]

Research

Dornase alfa has been shown to improve lung function in non-cystic fibrosis pre-term infants atelectasis.^[5][6]